Tech Center 1600 • Art Units: 1633 1642 1646
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16345124 | EXOSOMES AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 17633768 | Anti-Sclerostin Antibody Formulations | Final Rejection | AMGEN INC. |
| 17115360 | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection | Non-Final OA | ImmunityBio, Inc. |
| 18335515 | PRECURSOR PROTEINS AND KIT FOR TARGETED THERAPY | Non-Final OA | Hoffmann-La Roche Inc. |
| 18462692 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18453207 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17033050 | CELL-BASED CANCER VACCINES AND CANCER THERAPIES | Non-Final OA | Massachusetts Institute of Technology |
| 18016209 | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18268575 | STRUCTURE-BASED DESIGN AND DISCOVERY OF LONG-ACTING COCAINE HYDROLASE MUTANTS WITH IMPROVED BINDING AFFINITY TO NEONATAL FC RECEPTOR FOR TREATMENT OF SUBSTANCE USE DISORDERS AND ORGANOPHOSPHORUS TOXICITY | Non-Final OA | University of Kentucky Research Foundation |
| 18020342 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 17808348 | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 17000617 | CD5 CHIMERIC ANTIGEN RECEPTOR FOR ADOPTIVE T CELL THERAPY | Non-Final OA | Baylor College of Medicine |
| 17781945 | NANOPARTICLE COMPOSITIONS AND METHODS OF USE | Final Rejection | The Trustees of the University of Pennsylvania |
| 18046173 | COMBINATION | Final Rejection | AstraZeneca AB |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | Non-Final OA | Fred Hutchinson Cancer Center |
| 18342884 | PEPTIDE ANALOGS CAPABLE OF ENHANCING STIMULATION OF A GLIOMA-SPECIFIC CTL RESPONSE | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17727142 | METHOD FOR SINGLE-BASE GENOME EDITING USING CRISPR/CPF1 SYSTEM AND USES THEREOF | Non-Final OA | CHUNG ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 17753119 | CHIMERIC COSTIMULATORY RECEPTORS AND METHODS AND USES THEREOF | Non-Final OA | McMaster University |
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | Final Rejection | Janssen Biotech, Inc. |
| 18040306 | DIAGNOSIS METHOD FOR BLADDER CANCER | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 17919178 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | Final Rejection | City of Hope |
| 18261854 | ACE2-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF | Non-Final OA | National Research Council of Canada |
| 18357452 | METHODS AND COMPOSITIONS COMPRISING FUSION PROTEINS FOR THE IDENTIFICATION OF IMMUNOTHERAPY CELLS | Non-Final OA | Lankenau Institute for Medical Research |
| 18411101 | COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | iCell Gene Therapeutics Inc. |
| 17775791 | COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS | Final Rejection | UNIVERSITÄT HEIDELBERG |
| 17289877 | T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18044365 | CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME | Non-Final OA | GI CELL, INC. |
| 17042945 | METHOD AND KIT FOR DIAGNOSING AND FOR TREATMENT OF A CANCER BASED ON THE OVEREXPRESSION OF THE ADAMTSL5 GENE | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) |
| 18489222 | COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER | Final Rejection | RevImmune, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy